A treatment pulled off the market 30 years ago has won FDA approval again as the only drug specifically designated to treat morning sickness. That long-ago safety scare, prompted by hundreds of lawsuits claiming birth defects, proved to be a false alarm. Monday's FDA decision means a new version of the pill once called Bendectin is set to return to U.S. pharmacies under a different name — Diclegis. “We know safety-wise, there’s zero question,” said UTMB’s Dr. Gary Hankins, who headed one of the company-financed studies of Diclegis that led to its approval. The news also appears in the Dallas Morning News, the Columbus Dispatch, the Minneapolis Star Tribune and the New York Daily News, among other outlets. The Huffington Post also interviewed Hankins for a live web chat.